Shutterstock.com
Patients with migraine continue to benefit from preventive treatment with fremanezumab over the longer term, with sustained reductions in monthly migraine and headache days, a 12-month study in Neurology has suggested (10 September 2020)[1]
.
The monoclonal antibody, which targets the calcitonin gene-related peptide pathway, was evaluated as a monthly or quarterly preventive therapy over 52 weeks in 1,890 patients with either chronic migraine (CM) or episodic migraine (EM).
The researchers found that both treatment regimens were well tolerated and demonstrated sustained improvements in monthly migraine days (CM quarterly, -7.2 days; CM monthly, -8.0 days; EM quarterly, -5.2 days; EM monthly, -5.1 days), headache days (CM quarterly, -6.4 days; CM monthly, -6.8 days; EM quarterly, -4.4 days; EM monthly, -4.2 days), and headache-related disability for up to 12 months.
Adverse events, such as injection-site reactions, were broadly in line with previous studies, with no clinically significant adverse event patterns observed. There were also no serious cardiovascular-related adverse events related to fremanezumab.
“Fremanezumab continues to change the landscape of migraine prevention and treatment and provides a treatment option for patients with EM or CM to reduce their pain and disability while improving their quality of life,” the researchers concluded.
References
[1] Goadsby P, Silberstein S, Yeung P et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 2020. doi: 10.1212/WNL.0000000000010600
